Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 6/20 | 0.59 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | DHPS | P49366 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 2/20 | 0.40 |
| ▸ | NOS1 | P29475 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22864071 | 0.88 | IDO1 (0.55) | IDO1ADRB1ADRB2CYP2D6NFKB1 | |
| SCHEMBL29236958 | 0.83 | IDO1 (0.55) | IDO1DHPSAXLNOS1 | |
| SCHEMBL29236955 | 0.83 | IDO1 (0.55) | IDO1DHPSAXLNOS1 | |
| SCHEMBL29236956 | 0.83 | IDO1 (0.55) | IDO1DHPSAXLNOS1 | |
| SCHEMBL31046423 | 0.83 | IDO1 (0.55) | IDO1DHPSAXLNOS1 | |
| SCHEMBL22864292 | 0.82 | IDO1 (0.60) | IDO1ADRB1ADRB2HIF1AAXL | |
| SCHEMBL24630927 | 0.81 | IDO1 (0.59) | IDO1AXLNOS1 | |
| SCHEMBL22864253 | 0.80 | IDO1 (0.60) | IDO1ADRB1ADRB2CYP2D6NFKB1 | |
| SCHEMBL22864073 | 0.79 | ADRB2 (0.45) | IDO1ADRB1ADRB2CYP2D6NFKB1 | |
| SCHEMBL24630903 | 0.79 | IDO1 (0.43) | IDO1ADRB1ADRB2CYP2D6NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220315534-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315534-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | IDO1 3184/4885ADRB1 2/4885ADRB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.